Review of Liquid Chromatography-Mass Spectrometry-Based Proteomic Analyses of Body Fluids to Diagnose Infectious Diseases

Int J Mol Sci. 2022 Feb 16;23(4):2187. doi: 10.3390/ijms23042187.

Abstract

Rapid and precise diagnostic methods are required to control emerging infectious diseases effectively. Human body fluids are attractive clinical samples for discovering diagnostic targets because they reflect the clinical statuses of patients and most of them can be obtained with minimally invasive sampling processes. Body fluids are good reservoirs for infectious parasites, bacteria, and viruses. Therefore, recent clinical proteomics methods have focused on body fluids when aiming to discover human- or pathogen-originated diagnostic markers. Cutting-edge liquid chromatography-mass spectrometry (LC-MS)-based proteomics has been applied in this regard; it is considered one of the most sensitive and specific proteomics approaches. Here, the clinical characteristics of each body fluid, recent tandem mass spectroscopy (MS/MS) data-acquisition methods, and applications of body fluids for proteomics regarding infectious diseases (including the coronavirus disease of 2019 [COVID-19]), are summarized and discussed.

Keywords: COVID-19; biomarker discovery; bodily fluid; infectious disease; mass spectrometry; pathogen; proteomics.

Publication types

  • Review

MeSH terms

  • Body Fluids
  • COVID-19 Testing / methods
  • Chromatography, Liquid / methods*
  • Communicable Diseases / diagnosis*
  • Humans
  • Mass Spectrometry / methods*
  • Microbiological Techniques / methods*
  • Proteomics / methods*
  • Tandem Mass Spectrometry